Last reviewed · How we verify
NCT07533110: NOVASHIELD-RCT
Evaluation Of The Success Rate of NOVAMag® SHIELD In Two Different Advanced Bone Defects: A Randomized Controlled Trial
Phase 4 trial testing SHIELD technique with NOVAMag membrane in Alveolar Buccal Bone Dehiscences in 40 participants. Currently enrolling.
18 December 2026
Quick facts
| Lead sponsor | Egas Moniz - Cooperativa de Ensino Superior, CRL |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 19 March 2026 |
| Primary completion | 18 December 2026 |
| Estimated completion | 30 September 2027 |
| Sites | 1 location across Portugal |
Drugs / interventions tested
- SHIELD technique with NOVAMag membrane
Conditions studied
- Alveolar Buccal Bone Dehiscences — all drugs for Alveolar Buccal Bone Dehiscences →
- Socket Type 3 Subclass B — all drugs for Socket Type 3 Subclass B →
- Socket Type 3 Subclass C — all drugs for Socket Type 3 Subclass C →
Sponsor
Egas Moniz - Cooperativa de Ensino Superior, CRL — full company profile →
Who can join
Eligibility, any sex, with Alveolar Buccal Bone Dehiscences or Socket Type 3 Subclass B. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study hypothesizes that the SHIELD technique, when combined with a suitable bone graft material, enables successful immediate implant placement in Type 3 extraction sockets with buccal bone dehiscence, regardless of the extent of buccal bone loss. Specifically, it is proposed that the regenerative potential of the SHIELD technique is not significantly affected by the degree of buccal bone dehiscence, whether in compromised sockets (ST3 Subclass B, when a buccal dehiscence is present and extending 1/3 to 2/3 of the total length of the alveolus) or severely compromised sockets (ST3 Subclass C, for severe dehiscence passing more than 2/3 of the facial bone of the alveolus). All in all, this study aims to assess the clinical performance of the CE-approved medical device NOVAMag® SHIELD by evaluating its success rate and long-term suitability for the rehabilitation of edentulous regions in routine clinical settings. It further seeks to generate clinically meaningful evidence supporting the safety and efficacy of magnesium-based biomaterials in the management of complex post-extraction defects. In addition, the study investigates the CE-approved self-tapping conical implant VEGA® + to obtain comprehensive clinical data contributing to post-market surveillance and continuous product evaluation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07533110
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Egas Moniz - Cooperativa de Ensino Superior, CRL trials
Trials by the same sponsor.
- NCT07411833 — tDCS for Stress and Burnout in Higher Education · NA · enrolling by invitation
- NCT07190456 — Kinesiophobia vs. Task-Specific Fear: Defining Movement-Related Fear in ACL Reconstruction Patients · NA · recruiting
- NCT07352384 — Evaluation of the Efficacy of Neuromodulation in the Control of Chronic Orofacial Pain · NA · enrolling by invitation
- NCT07079280 — Comparing Vascular Responses to Aerobic Exercise With and Without Blood Flow Restriction in Young and Older Adults · NA · not yet recruiting
- NCT07021144 — VA|PREVENTION: Randomized Controlled Trial of a Person-Centred Digital Intervention to Prevent Diabetes in High-Risk Adu · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07533110 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Egas Moniz - Cooperativa de Ensino Superior, CRL
- Last refreshed: 16 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07533110.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing